Identification

Name

Torasemide

Accession Number

DB00214

Description

Torasemide is a high-ceiling loop diuretic.¹ Structurally, it is a pyridine-sulfnyl urea used as an antihypertensive agent.⁴ On the FDA records, torasemide was developed and first introduced by the company Teva Pharmaceuticals and FDA approved in 2002.⁹ However, torasemide was first approved for clinical use by the FDA on 1993.¹²

Type

Small Molecule

Groups

Approved

Structure

3D

Download

MOLSDF3D-SDFPDBSMILESInChI

Similar Structures

Structure for Torasemide (DB00214)

×

Close

Weight

Average: 348.42
Monoisotopic: 348.125611216

Chemical Formula

C₁₆H₂₀N₄O₃S

Synonyms

• 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea
• N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamide
• Torasemida
• Torasemide
• Torasémide
• Torasemidum
• Torsemide

External IDs

• AC-4464
• AC4464
• BM-02.015
• BM-02015
• BM02.015

Pharmacology

Indication

Torasemide is indicated for the treatment of edema associated with congestive heart failure, renal or hepatic diseases. From this condition, it has been observed that torasemide is very effective in cases of kidney failure.^Label

Edema is considered when swelling is observed due to the trap of fluid in the body tissue. It is mainly located in feet, ankles and legs but it can also be extended to other parts such as face, hands and abdomen or even the whole body.¹⁰

As well, torasemide is approved to be used as an antihypertensive agent either alone or in combination with other antihypertensives.^Label

Hypertension is defined by the presence of high blood pressure. This is caused by an increase in the amount of blood pumped which in order produces the narrowing of the arteries.¹¹

Associated Conditions

• Edema
• High Blood Pressure (Hypertension)

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

It is widely known that administration of torasemide can attenuate renal injury and reduce the severity of acute renal failure. This effect is obtained by increasing urine output and hence, facilitating fluid, acid-base and potassium control.² This effect is obtained by the increase in the excretion of urinary sodium and chloride.³

Several reports have indicated that torasemide presents a long-lasting diuresis and less potassium excretion which can be explained by the effect that torasemide has on the renin-angiotensin-aldosterone system. This effect is very similar to the effect observed with the administration of combination therapy with furosemide and spironolactone and it is characterized by a decrease in plasma brain natriuretic peptide and improved measurements of left ventricular function.³

Above the aforementioned effect, torasemide presents a dual effect .in which the inhibition of aldosterone which donates torasemide with a potassium-sparing action.²

Torasemide has been shown to reduce extracellular fluid volume and blood pressure in hypertensive patients suffering from chronic kidney disease. As well, some reports have indicated that torasemide can reduce myocardial fibrosis by reducing the collagen accumulation. This effect is suggested to be related to the decrease in aldosterone which in order has been shown to reduce the production of the enzyme procollagen type I carboxy-terminal proteinase which is known to be overexpressed in heart failure patients.¹

Mechanism of action

As mentioned above, torasemide is part of the loop diuretics and thus, it acts by reducing the oxygen demand in the medullary thick ascending loop of Henle by inhibiting the Na+/K+/Cl- pump on the luminal cell membrane surface.² This action is obtained by the binding of torasemide to a chloride ion-binding site of the transport molecule.¹²

Torasemide is known to have an effect in the renin-angiotensin-aldosterone system by inhibiting the downstream cascade after the activation of angiotensin II. This inhibition will produce a secondary effect marked by the reduction of the expression of aldosterone synthase, TGF-B1 and thromboxane A2 and a reduction on the aldosterone receptor binding.^2,3

Target	Actions	Organism
ASolute carrier family 12 member 1	inhibitor	Humans
ASolute carrier family 12 member 2	inhibitor	Humans

Absorption

Torasemide is the diuretic with the highest oral bioavailability even in advanced stages of chronic kidney disease.¹ This bioavailability tends to be higher than 80% regardless of the patient condition. The maximal serum concentration is reported to be of 1 hour and the absorption parameters are not affected by its use concomitantly with food.³

Volume of distribution

The volume of distribution of torasemide is 0.2 L/kg.⁵

Protein binding

Torasemide is found to be highly bound to plasma proteins, representing over 99% of the administered dose.⁵

Metabolism

Torasemide is extensively metabolized in the liver and only 20% of the dose remains unchanged and it is recovered in the urine.⁵ Metabolized via the hepatic CYP2C8 and CYP2C9 mainly by reactions of hydroxylation, oxidation and reduction to 5 metabolites.⁷ The major metabolite, M5, is pharmacologically inactive. There are 2 minor metabolites, M1, possessing one-tenth the activity of torasemide, and M3, equal in activity to torasemide. Overall, torasemide appears to account for 80% of the total diuretic activity, while metabolites M1 and M3 account for 9% and 11%, respectively.⁶

Hover over products below to view reaction partners

• Torasemide
  • Torasemide M1 (hydroxytorsemide)
    • Torasemide M5
  • Torasemide M4
  • Torasemide M2
  • Torasemide M3

Route of elimination

Torasemide is mainly hepatically processed and excreted in the feces from which about 70-80% of the administered dose is excreted by this pathway. On the other hand, about 20-30% of the administered dose is found in the urine.¹²

Half-life

The average half-life of torasemide is 3.5 hours.³

Clearance

The clearance rate of torasemide is considerably reduced by the presence of renal disorders.⁵

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

The oral LD50 of torasemide in the rat is 5 g/kg. When overdose occurs, there is a marked diuresis with the danger of loss of fluid and electrolytes which has been seen to lead to somnolence, confusion, hypotension, hyponatremia, hypokalemia, hypochloremic alkalosis, hemoconcentration dehydration and circulatory collapse. This effects can include some gastrointestinal disturbances.¹³

There is no increase in tumor incidence with torasemide and it is proven to not be mutagenic, not fetotoxic or teratogenic.^Label

Affected organisms

• Humans and other mammals

Pathways

Pathway	Category
Torsemide Action Pathway	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

• Approved
• Vet approved
• Nutraceutical
• Illicit
• Withdrawn
• Investigational
• Experimental
• All Drugs

Drug	Interaction
Unlock Additional Data
Abacavir	Torasemide may increase the excretion rate of Abacavir which could result in a lower serum level and potentially a reduction in efficacy.
Abatacept	The metabolism of Torasemide can be increased when combined with Abatacept.
Abiraterone	The metabolism of Torasemide can be decreased when combined with Abiraterone.
Acarbose	The therapeutic efficacy of Acarbose can be increased when used in combination with Torasemide.
Acebutolol	Torasemide may increase the hypotensive activities of Acebutolol.
Aceclofenac	The therapeutic efficacy of Torasemide can be decreased when used in combination with Aceclofenac.
Acemetacin	The therapeutic efficacy of Torasemide can be decreased when used in combination with Acemetacin.
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Torasemide.
Acetaminophen	Torasemide may increase the excretion rate of Acetaminophen which could result in a lower serum level and potentially a reduction in efficacy.
Acetohexamide	The therapeutic efficacy of Acetohexamide can be increased when used in combination with Torasemide.

Additional Data Available

Extended Description
Extended Description
Extended description of the mechanism of action and particular properties of each drug interaction.
Learn more
Severity
Severity
A severity rating for each drug interaction, from minor to major.
Learn more
Evidence Level
Evidence Level
A rating for the strength of the evidence supporting each drug interaction.
Learn more
Action
Action
An effect category for each drug interaction. Know how this interaction affects the subject drug.
Learn more

Food Interactions

• Take with or without food. Food delays the Cmax by 30 minutes but does not impact efficacy.

Products

Product Images

PreviousNext

International/Other Brands

Britomar (Ferrer) / Diuver (Pliva) / Examide (Apex) / Luprac (Tanabe Mitshubishi Pharma) / Torem (Berlin-Chemie) / Trifas (Meranini)

Brand Name Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Demadex	Tablet	20 mg/1	Oral	Roche Pharmaceuticals	2007-02-06	Not applicable
Demadex	Tablet	20 mg/1	Oral	Physicians Total Care, Inc.	2009-10-21	Not applicable
Demadex	Tablet	10 mg/1	Oral	Meda Pharmaceuticals Inc.	2009-02-20	2009-08-04
Demadex	Tablet	5 mg/1	Oral	Meda Pharmaceuticals Inc.	2015-01-01	2014-12-19
Demadex	Tablet	100 mg/1	Oral	MEDA Pharmaceuticals	2015-01-01	2020-07-31
Demadex	Tablet	10 mg/1	Oral	Roche Pharmaceuticals	2007-02-06	Not applicable
Demadex	Injection, solution	10 mg/1mL	Intravenous	Roche Pharmaceuticals	2007-02-06	Not applicable
Demadex	Tablet	5 mg/1	Oral	Meda Pharmaceuticals Inc.	2009-02-20	2009-08-04
Demadex	Tablet	100 mg/1	Oral	Meda Pharmaceuticals Inc.	2009-02-20	2009-08-04
Demadex	Tablet	20 mg/1	Oral	MEDA Pharmaceuticals	2015-01-01	2018-11-30

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End	Region	Image
Unlock Additional Data
Torsemide	Tablet	100 mg/1	Oral	Par Pharmaceutical	2003-05-28	2011-08-10
Torsemide	Injection, solution	10 mg/1mL	Intravenous	General Injectables & Vaccines	2010-06-01	2012-06-01
Torsemide	Tablet	10 mg/1	Oral	Cardinal Health	2010-01-14	2010-11-30
Torsemide	Tablet	20 mg/1	Oral	Sun Pharmaceutical Industries Limited	2008-02-26	2017-02-18
Torsemide	Tablet	10 mg/1	Oral	Av Kare, Inc.	2017-04-03	Not applicable
Torsemide	Tablet	20 mg/1	Oral	Av Pak	2014-10-07	Not applicable
Torsemide	Tablet	10 mg/1	Oral	bryant ranch prepack	2011-01-01	Not applicable
Torsemide	Tablet	5 mg/1	Oral	Camber Pharmaceuticals, Inc.	2011-01-01	Not applicable
Torsemide	Tablet	100 mg/1	Oral	Camber Pharmaceuticals, Inc.	2011-01-01	Not applicable
Torsemide	Tablet	20 mg/1	Oral	Aurobindo Pharma Limited	2007-10-17	Not applicable

Additional Data Available

Application Number
Application Number
A unique ID assigned by the FDA when a product is submitted for approval by the labeller.
Learn more
Product Code
Product Code
A governmentally-recognized ID which uniquely identifies the product within its regulatory market.
Learn more

Categories

ATC Codes

C03CA04 — Torasemide

• C03CA — Sulfonamides, plain
• C03C — HIGH-CEILING DIURETICS
• C03 — DIURETICS
• C — CARDIOVASCULAR SYSTEM

G01AE10 — Combinations of sulfonamides

• G01AE — Sulfonamides
• G01A — ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS
• G01 — GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS
• G — GENITO URINARY SYSTEM AND SEX HORMONES

Drug Categories

• Antihypertensive Agents
• Antihypertensive Agents Indicated for Hypertension
• Cardiovascular Agents
• Cytochrome P-450 CYP2C8 Substrates
• Cytochrome P-450 CYP2C9 Inhibitors
• Cytochrome P-450 CYP2C9 Inhibitors (strength unknown)
• Cytochrome P-450 CYP2C9 Substrates
• Cytochrome P-450 Enzyme Inhibitors
• Cytochrome P-450 Substrates
• Diuretics
• High-Ceiling Diuretics
• Hyperglycemia-Associated Agents
• Hypotensive Agents
• Increased Diuresis at Loop of Henle
• Membrane Transport Modulators
• Natriuretic Agents
• Non Potassium Sparing Diuretics
• OATP1B1/SLCO1B1 Substrates
• Ototoxic agents
• Pyridines
• Sodium Potassium Chloride Symporter Inhibitors
• Sulfonamides
• Sulfones
• Sulfur Compounds

Chemical TaxonomyProvided by Classyfire

Description

This compound belongs to the class of organic compounds known as pyridinesulfonamides. These are heterocyclic compounds containing a pyridine ring substituted by one or more sulfonamide groups.

Kingdom

Organic compounds

Super Class

Organoheterocyclic compounds

Class

Pyridines and derivatives

Sub Class

Pyridinesulfonamides

Direct Parent

Pyridinesulfonamides

Alternative Parents

Toluenes / Sulfonylureas / Dihydropyridines / Secondary ketimines / Organosulfonic acids and derivatives / Heteroaromatic compounds / Aminosulfonyl compounds / Propargyl-type 1,3-dipolar organic compounds / Carboximidic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives

show 4 more

Substituents

Aminosulfonyl compound / Aromatic heteromonocyclic compound / Azacycle / Benzenoid / Carboximidic acid derivative / Dihydropyridine / Heteroaromatic compound / Hydrocarbon derivative / Hydropyridine / Monocyclic benzene moiety / Organic 1,3-dipolar compound / Organic nitrogen compound / Organic oxide / Organic oxygen compound / Organic sulfonic acid or derivatives / Organonitrogen compound / Organooxygen compound / Organopnictogen compound / Organosulfonic acid or derivatives / Organosulfur compound / Propargyl-type 1,3-dipolar organic compound / Pyridine-3-sulfonamide / Secondary ketimine / Sulfonyl / Sulfonylurea / Toluene

show 16 more

Molecular Framework

Aromatic heteromonocyclic compounds

External Descriptors

secondary amino compound, aminopyridine, N-sulfonylurea (CHEBI:9637)

Chemical Identifiers

UNII

W31X2H97FB

CAS number

56211-40-6

InChI Key

NGBFQHCMQULJNZ-UHFFFAOYSA-N

InChI

InChI=1S/C16H20N4O3S/c1-11(2)18-16(21)20-24(22,23)15-10-17-8-7-14(15)19-13-6-4-5-12(3)9-13/h4-11H,1-3H3,(H,17,19)(H2,18,20,21)

IUPAC Name

1-({4-[(3-methylphenyl)amino]pyridin-3-yl}sulfonyl)-3-(propan-2-yl)urea

SMILES

CC(C)NC(=O)NS(=O)(=O)C1=C(NC2=CC=CC(C)=C2)C=CN=C1

References

Synthesis Reference

Fritz Topfmeier, Gustav Lettenbauer, "Process for the preparation of a stable modification of torasemide." U.S. Patent USRE0345806, issued June, 1975.

USRE0345806

General References

1. Lopez B, Gonzalez A, Hermida N, Laviades C, Diez J: Myocardial fibrosis in chronic kidney disease: potential benefits of torasemide. Kidney Int Suppl. 2008 Dec;(111):S19-23. doi: 10.1038/ki.2008.512. [PubMed:19034320]
2. Li XM, Jin DX, Cong HL: Could torasemide be a prophylactic agent of contrast induced acute kidney injury? A review about this field. Eur Rev Med Pharmacol Sci. 2013 Jul;17(14):1845-9. [PubMed:23877845]
3. Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM: A reappraisal of loop diuretic choice in heart failure patients. Am Heart J. 2015 Mar;169(3):323-33. doi: 10.1016/j.ahj.2014.12.009. Epub 2015 Jan 6. [PubMed:25728721]
4. Dunn CJ, Fitton A, Brogden RN: Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs. 1995 Jan;49(1):121-42. [PubMed:7705212]
5. Knauf H, Mutschler E: Clinical pharmacokinetics and pharmacodynamics of torasemide. Clin Pharmacokinet. 1998 Jan;34(1):1-24. doi: 10.2165/00003088-199834010-00001. [PubMed:9474471]
6. Neugebauer G, Besenfelder E, von Mollendorff E: Pharmacokinetics and metabolism of torasemide in man. Arzneimittelforschung. 1988 Jan;38(1A):164-6. [PubMed:3370063]
7. Barroso MB, Alonso RM, Jimenez RM: Simultaneous determination of torasemide and its major metabolite M5 in human urine by high-performance liquid chromatography-electrochemical detection. J Chromatogr Sci. 2001 Nov;39(11):491-6. [PubMed:11718311]
8. Coleman J., Cox A. and Cowley N. (2011). Side Effects of Drugs Annual. Elsevier.
9. FDA approvals [Link]
10. Cleveland Clinic [Link]
11. Hypertension Canada [Link]
12. Indian Journal of Clinical Practice [Link]
13. EMC [Link]

External Links

Human Metabolome Database

HMDB0014359

KEGG Drug

D00382

PubChem Compound

41781

PubChem Substance

46504760

ChemSpider

38123

BindingDB

64107

RxNav

38413

ChEBI

9637

ChEMBL

CHEMBL1148

ZINC

ZINC000000005823

Therapeutic Targets Database

DAP000745

PharmGKB

PA451733

RxList

RxList Drug Page

PDRhealth

PDRhealth Drug Page

Wikipedia

Torasemide

FDA label

Download (92.4 KB)

MSDS

Download (74.7 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Treatment	Congestive Heart Failure (CHF)	1
4	Completed	Treatment	High Blood Pressure (Hypertension)	2
4	Completed	Treatment	Right Heart Failure / Tricuspid valve incompetence	1
4	Recruiting	Treatment	Cardiovascular Heart Disease / High Blood Pressure (Hypertension)	1
4	Recruiting	Treatment	Heart Failure	2
4	Terminated	Treatment	Compensated Heart Failure	1
4	Unknown Status	Treatment	Arterial Hypertension / Chronic Heart Failure (CHF)	1
3	Recruiting	Treatment	Heart Failure	1
2	Completed	Prevention	Preeclampsia	1
2, 3	Completed	Treatment	Heart Failure	1

Pharmacoeconomics

Manufacturers

• Hoffmann la roche inc
• Bedford laboratories
• Luitpold pharmaceuticals inc
• Meda pharmaceuticals inc
• Apotex inc etobicoke site
• Aurobindo pharma ltd
• Hetero drugs ltd
• Par pharmaceutical inc
• Pliva pharmaceutical industry inc
• Roxane laboratories inc
• Sun pharmaceutical industries ltd
• Teva pharmaceuticals usa inc

Packagers

• American Regent
• Apotex Inc.
• Aurobindo Pharma Ltd.
• Camber Pharmaceuticals Inc.
• Cardinal Health
• Diversified Healthcare Services Inc.
• F Hoffmann-La Roche Ltd.
• General Injectables and Vaccines Inc.
• Greenstone LLC
• Heartland Repack Services LLC
• Hetero Drugs Ltd.
• Ivax Pharmaceuticals
• Mckesson Corp.
• Meda AB
• Murfreesboro Pharmaceutical Nursing Supply
• Neuman Distributors Inc.
• Palmetto Pharmaceuticals Inc.
• Par Pharmaceuticals
• Physicians Total Care Inc.
• Pliva Inc.
• Preferred Pharmaceuticals Inc.
• Prepak Systems Inc.
• Resource Optimization and Innovation LLC
• Roxane Labs
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• UDL Laboratories
• Vangard Labs Inc.

Dosage Forms

Form	Route	Strength
Injection, solution	Intravenous	10 mg/1mL
Tablet	Oral	10 mg/1
Tablet	Oral	100 mg/1
Tablet	Oral	20 mg/1
Tablet	Oral	5 mg/1
Liquid	Intravenous
Tablet	Oral
Tablet		10 MG
Tablet		2.5 MG
Tablet		200 MG
Tablet		20 MG
Tablet		5 MG
Tablet		100 MG
Tablet		50 MG

Prices

Unit description	Cost	Unit
Demadex 100 mg tablet	5.69USD	tablet
Torsemide 100 mg tablet	3.16USD	tablet
Demadex 20 mg tablet	1.59USD	tablet
Demadex 10 mg tablet	1.39USD	tablet
Demadex 5 mg tablet	1.28USD	tablet
Torsemide 20 mg tablet	0.85USD	tablet
Torsemide 10 mg tablet	0.73USD	tablet
Torsemide 5 mg tablet	0.66USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Not Available

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	163-164 °C	'MSDS'
water solubility	Soluble	'MSDS'
logP	3.356	'MSDS'
pKa	7.1	'FDA label'

Predicted Properties

Property	Value	Source
Water Solubility	0.0596 mg/mL	ALOGPS
logP	1.76	ALOGPS
logP	1.86	ChemAxon
logS	-3.8	ALOGPS
pKa (Strongest Acidic)	5.92	ChemAxon
pKa (Strongest Basic)	4.2	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	3	ChemAxon
Polar Surface Area	100.19 Å2	ChemAxon
Rotatable Bond Count	4	ChemAxon
Refractivity	91.89 m3·mol-1	ChemAxon
Polarizability	36.15 Å3	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET Features

Property	Value	Probability
Human Intestinal Absorption	+	0.9156
Blood Brain Barrier	+	0.6871
Caco-2 permeable	-	0.5374
P-glycoprotein substrate	Non-substrate	0.799
P-glycoprotein inhibitor I	Non-inhibitor	0.7695
P-glycoprotein inhibitor II	Non-inhibitor	0.8232
Renal organic cation transporter	Non-inhibitor	0.9185
CYP450 2C9 substrate	Substrate	0.6049
CYP450 2D6 substrate	Non-substrate	0.9116
CYP450 3A4 substrate	Non-substrate	0.7558
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.6692
CYP450 2D6 inhibitor	Non-inhibitor	0.923
CYP450 2C19 inhibitor	Non-inhibitor	0.9025
CYP450 3A4 inhibitor	Inhibitor	0.5905
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.6324
Ames test	Non AMES toxic	0.9133
Carcinogenicity	Non-carcinogens	0.8366
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	1.8740 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9854
hERG inhibition (predictor II)	Non-inhibitor	0.8668

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-03di-0090000000-bcaf4981571fb662df86
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-03di-0090000000-00cc7369c05298ea1c97
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-03di-0490000000-60171fe07a2f255596e3
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-01ot-2950000000-359d6835f9bf703a0701
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-000t-3910000000-a5ec65a6dbedfe7a30d3
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-0564-6900000000-051171526b146f5d076c
LC-MS/MS Spectrum - LC-ESI-QFT , negative	LC-MS/MS	splash10-03di-0190000000-1b2efe76058c7bf06b4a
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-03di-0091000000-548edfa45514c501788d
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-03di-0090000000-d7326b2b38380cd06e26
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-03di-0490000000-b9f43c4768937947d77f
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-001i-0940000000-7b7084526f7c13bf6443
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-00lr-0910000000-81aa8c9ff5d9a3cd3c10
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0159-0900000000-87860a9931a8414432cf
MS/MS Spectrum - , positive	LC-MS/MS	splash10-03di-1590000000-1b7d966c20cec1451f6c
MS/MS Spectrum - , positive	LC-MS/MS	splash10-03di-0490000000-bd8b6af3fe8d0f10e117
MS/MS Spectrum - , positive	LC-MS/MS	splash10-02ai-2940000000-5beb0e7e25d393903803
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-03di-0390000000-314819093d7d5a1f48f4

×

Unlock Data

There is additional data available for commercial users including Adverse Effects, Contraindications, and Blackbox Warnings. Contact us to learn more about these and other features.

Learn more

Drug created on June 13, 2005 07:24 / Updated on June 12, 2020 11:40